Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0901 in Advanced/Metastatic Gastric or GEJ Adenocarcinoma
NCT07143604Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of sonesitatug vedotin in gastric cancer (GC), gastroesophageal junction cancer, sponsored by AstraZeneca. Started Aug 2025; status: active, not recruiting.
02
Drugs
sonesitatug vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07143604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07143604.